Phaseline

Companies › RayzeBio

RayzeBio: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RYZ101
Actinium-225 labeled somatostatin receptor agonist (SSTR-targeting radiopharmaceutical)
SSTR2Phase 3GEP-NET; SCLC,Extensive Stage; Metastatic Breast CancerDec 2026
RYZ401
Ac-225-based targeted alpha therapy for somatostatin receptor expression
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5Phase 1GEP-NETFeb 2027
RYZ801
GPC3-targeted alpha-emitting radiotherapeutic (Ac-225 conjugate)
GPC3Phase 1Hepatocellular Carcinoma (HCC)Jun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05477576RYZ101Phase 3GEP-NETOncologyDec 2026
NCT07165132RYZ401Phase 1GEP-NETOncologyFeb 2027
NCT05595460RYZ101Phase 1SCLC,Extensive StageOncologyJul 2027
NCT06590857RYZ101Phase 1Metastatic Breast CancerOncologyOct 2028
NCT06726161RYZ801Phase 1Hepatocellular Carcinoma (HCC)OncologyJun 2030

Targets

SSTR2 (2) GPC3 (1) SSTR1 (1) SSTR3 (1) SSTR4 (1) SSTR5 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP ITM Solucin Debiopharm International Nanjing Chia-tai Tianqing Pharmaceutical Orano Med

Companies built like this

PharmaMar Day One Biopharmaceuticals ArriVent BioPharma Nuvalent Jiangsu Alphamab Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.